Journal of Autism and Developmental Disorders

, Volume 44, Issue 10, pp 2558–2567

In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder

  • Nicole B. Gidaya
  • Brian K. Lee
  • Igor Burstyn
  • Michael Yudell
  • Erik L. Mortensen
  • Craig J. Newschaffer
Original Paper

DOI: 10.1007/s10803-014-2128-4

Cite this article as:
Gidaya, N.B., Lee, B.K., Burstyn, I. et al. J Autism Dev Disord (2014) 44: 2558. doi:10.1007/s10803-014-2128-4

Abstract

We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark’s health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child’s risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.

Keywords

Autism spectrum disorders Selective serotonin reuptake inhibitors Pregnancy Depression 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Nicole B. Gidaya
    • 1
  • Brian K. Lee
    • 1
  • Igor Burstyn
    • 1
  • Michael Yudell
    • 1
  • Erik L. Mortensen
    • 2
  • Craig J. Newschaffer
    • 3
  1. 1.Drexel University, School of Public Health, Nesbitt HallPhiladelphiaUSA
  2. 2.Institut for FolkesundhedsvidenskabUniversity of CopenhagenCopenhagen KDenmark
  3. 3.A.J. Drexel Autism InstituteDrexel UniversityPhiladelphiaUSA

Personalised recommendations